Small diameter polycaprolactone vascular grafts are patent in sheep carotid bypass but require antithrombotic therapy.
Shu FangAlexander Høgsted AhlmannLouise LanghornKamal Hany HusseinJens Ahm SørensenXiaowei GuanSøren Paludan SheikhLars Peter Schoedt RiberDitte Caroline AndersenPublished in: Regenerative medicine (2021)
Background: Polycaprolactone (PCL) scaffolds exhibit high biocompatibility and are attractive as vascular conduits. Materials & methods: PCL tubes were cultivated in bioreactor with human adipose regenerative cells to assess ex vivo cytocompatibility, whereas in vivo PCL tube patency was evaluated in sheep carotid bypass with and without antithrombotic treatment. Results: Ex vivo results revealed increasing adipose regenerative cells on PCL using dynamic bioreactor culturing. In vivo data showed that 67% (2/3) of grafts in the antithrombotic group were patent at day 28, while 100% (3/3) of control grafts were occluded already during the first week due to thrombosis. Histology showed that patent PCL grafts were recellularized by host cells. Conclusion: PCL tubes may work as small diameter vascular scaffolds under antithrombotic treatment.
Keyphrases
- induced apoptosis
- tissue engineering
- cell cycle arrest
- stem cells
- atrial fibrillation
- endoplasmic reticulum stress
- wastewater treatment
- adipose tissue
- insulin resistance
- pulmonary embolism
- randomized controlled trial
- signaling pathway
- oxidative stress
- endothelial cells
- cell death
- metabolic syndrome
- cell proliferation
- big data
- skeletal muscle
- replacement therapy
- bone marrow
- optic nerve
- electronic health record
- study protocol
- deep learning